Printer Friendly

IMMUCOR REPORTS YEAR-END AND FOURTH QUARTER RESULTS

 IMMUCOR REPORTS YEAR-END AND FOURTH QUARTER RESULTS
 NORCROSS, Ga., July 27 /PRNewswire/ -- Immucor, Inc.


(NASDAQ-NMS: BLUD), maker of blood bank reagent systems and related products, announced today net income for the year ended May 31, 1992, totaled $3,043,496, compared to $3,097,370 a year ago.
 Earnings per share for the year were $.35 vs. $.38 per share last year. For the three-month period, net income totaled $635,696, compared to $881,670 a year ago. Earnings per share were $.08 for the fourth quarter, vs. $.10 per share last year.
 Revenues for the year ended May 31, 1992, increased 32 percent to $27,262,602 vs. $20,617,939 a year ago. Revenues for the fourth quarter were $7,343,581, compared to $6,290,087 last year.
 On July 2, the company announced it expected to report a decline in fourth quarter earnings and flat year-end earnings, as compared to the same periods last year. Commenting on these results, Edward L. Gallup, president of Immucor, said: "Investment income for the year decreased $475,500 when compared to last year. This decline was caused by a non- recurring gain on the sale of a long-term investment last year, combined with declining interest rates this year, which reduced income earned on cash reserves. Other factors contributing to the decline in fourth quarter net income were increased spending in Germany to support marketing and sales activities, a decline in blood collection bag sales in Germany, and a decline in domestic gross margin."
 Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used primarily by hospitals and blood banks in a number of tests performed to detect and identify certain properties of the cell and serum components of human blood prior to blood transfusion. Through its German and Italian subsidiaries, the company also sells blood bags for the collection, storage and administration of human blood, HLA products used primarily in human organ transplantation, DNA probes used in paternity testing and forensic medicine, and tests for certain infectious diseases.
 IMMUCOR INC.
 Statements of Income
 (Unaudited)
 3 months ended 12 months ended
 5/31/92 5/31/91 5/31/92 5/31/91
 Net sales $7,343,581 $6,290,087 $27,262,602 $20,617,939
 Cost of sales 3,266,920 2,675,523 11,353,638 8,878,584
 Gross profit 4,076,661 3,614,564 15,908,964 11,739,355
 Research and
 development 101,992 164,889 481,220 480,692
 Selling, general and
 administrative 3,035,087 2,280,368 10,990,739 7,492,060
 Total operating
 expenses 3,137,079 2,445,257 11,471,959 7,972,752
 Income from
 operations 939,582 1,169,307 4,437,005 3,766,603
 Other income 170,387 214,388 802,736 1,278,262
 Interest expense (194,368) (179,233) (631,341) (361,914)
 Other (17,978) 34,894 (39,504) (14,408)
 Total other (41,959) 70,049 131,891 901,940
 Income before income
 taxes 897,623 1,239,356 4,568,896 4,668,543
 Provision for
 income taxes 261,927 357,686 1,525,400 1,571,173
 Net income $ 635,696 $ 881,670 $3,043,496 $ 3,097,370
 Net income per common
 and common equivalent
 share $0.08 $0.10 $0.35 $0.38
 Balance sheet available upon request.
 -0- 7/27/92
 /CONTACT: Richard J. Still, vice president-finance of Immucor Inc., 404-441-2051/
 (BLUD) CO: Immucor, Inc. ST: Georgia IN: MTC SU: ERN


BN-EA -- AT001 -- 3325 07/27/92 08:02 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 27, 1992
Words:601
Previous Article:NEW DEVICE SAVES MONEY, BRINGS DATA/VOICE INTEGRATION TO THE MASSES
Next Article:NATIONSBANK ANNOUNCES EXECUTION OF DEFINITIVE AGREEMENT
Topics:


Related Articles
IMMUCOR REPORTS YEAR-END AND FOURTH QUARTER RESULTS
Immucor Reports Second Quarter Results
Immucor Announces Record Results for Fourth Quarter, Fiscal 1999; 72% Increase in Net Income for Fiscal 1999.
Immucor Announces Fiscal Fourth Quarter and Full Year Results.
Immucor Announces Covenant Waiver and Reset With Senior Lender, Fiscal Fourth Quarter and Full Year Results.
Immucor Earns $1.3 Million in Net Income for the Fiscal First Quarter; Financial Results Reflect Success of Turnaround Efforts.
Immucor Schedules Fourth Quarter and Fiscal 2003 Year End Earnings Release and Conference Call.
Resending With Additional Information -- Immucor Schedules Fourth Quarter And Fiscal 2003 Year End Earnings Release and Conference Call.
Immucor Announces Record Fiscal Fourth Quarter and Record Year End Results.
Immucor Announces Record Year End and Fiscal Fourth Quarter Results.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters